Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rAls3p-N
- Development stage
- Unknown
- Lead developer
- The Lundquist Institute
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
rAls3p-N is a recombinant vaccine antigen consisting of the N-terminal domain of the Candida albicans agglutinin-like sequence 3 (Als3) protein, a cell wall glycoprotein that functions as an adhesin and invasin. Developed by The Lundquist Institute and NovaDigm Therapeutics, rAls3p-N is formulated with aluminum hydroxide (as NDV-3 or NDV-3A) to act as an immunotherapeutic vaccine. It stimulates robust humoral and cellular (Th1/Th17) immune responses, generating antibodies that block fungal adhesion and invasion of host tissues. Due to structural homology between Als3 and Staphylococcus aureus clumping factor A (ClfA), the vaccine provides cross-kingdom protection against both Candida species (including C. albicans and C. auris) and S. aureus (including MRSA).
- Other names
- recombinant agglutinin-like sequence 3 protein N-terminal domainrecombinant Als3 protein N-terminusrecombinant Als3p N-terminusrecombinant N-terminus of agglutinin-like sequence 3 protein
Beyond the preview
Go deeper on rAls3p-N.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rAls3p-N.